Combining obinutuzumab with radiation for refractory DLBCL: Retrospective safety and efficacy analysis
Last Updated: Wednesday, July 10, 2024
A retrospective review of patients with treatment-refractory DLBCL (N = 7) who received concurrent radiation and obinutuzumab found the treatment to be well tolerated without excessive treatment-related toxicity. No grade 3 or greater treatment-related toxicity was observed. Four of the 7 patients had a complete response at the radiated site on first postradiation imaging, and median PFS and OS were 30 months.
Advertisement
News & Literature Highlights
